Tenderwize
Wróć do wyszukiwania

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 338 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fusidinsäure/Betamethason (ATC-Code nach WHO: D07CC01)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Fusidinsäure/Betamethason.
  • Open-House participation model with equal access for all interested qualifying pharmaceutical companies.
Pokaż pełne podsumowanie

This is an Open-House pharmaceutical supply arrangement for Fusidinsäure/Betamethason (ATC D07CC01) led by AOK PLUS. It is non-exclusive, open to all qualifying pharmaceutical companies, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents were not provided beyond the XML notice text, so document-specific instructions cannot be fully verified.

Ryzyka

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must accept the participation conditions and the rebate agreement terms.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

Supply lot for non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for the active substance Fusidinsäure/Betamethason (ATC D07CC01). The lot is an Open-House model, so any interested qualifying pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, specifically Dresden in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 31, 2027

Szczegóły zamówienia

Data publikacji
21 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
330350-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3